Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Saccharomyces boulardii as an emerging alternative to bacterial probiotics: A comprehensive review. Local targets link to admitted publications; unresolved targets remain external evidence.
Introduction to the human gut microbiota
10.1042/bcj20160510 · 2017 · External reference
The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic
10.1038/nrgastro.2014.66 · 2014 · External reference
Probiotics: mechanism of action, health benefits and their application in food industries
10.3389/fmicb.2023.1216674 · 2023 · External reference
Probiotics-based foods and beverages as future foods and their overall safety and regulatory claims
10.1016/j.fufo.2021.100013 · 2021 · External reference
Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review
10.3390/ph16111615 · 2023 · External reference
Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review
10.2147/ceg.s85574 · 2015 · External reference
Effects of probiotics on gut microbiota: an overview
10.3390/ijms25116022 · 2024 · External reference
Prebiotics and probiotics for gastrointestinal disorders
10.3390/nu16060778 · 2024 · External reference
More information needed on probiotic supplement product labels
10.1007/s11606-019-05077-5 · 2019 · External reference
Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives
10.3390/microorganisms12030430 · 2024 · External reference
Lactic acid bacteria in Asian fermented foods and their beneficial roles in human health
10.1007/s10068-024-01634-9 · 2024 · External reference
Bile acids as modulators of gut microbiota composition and function
10.1080/19490976.2023.2172671 · 2023 · External reference
Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases
10.1007/s00284-020-02053-9 · 2020 · External reference
Eukaryotic probiotic Saccharomyces boulardii application in clinical trails: a review
2020 · External reference
Unresolved reference
2023 · External reference
Genomic and phenotypic comparison of Saccharomyces cerevisiae and Saccharomyces boulardii
2025 · External reference
Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review
10.1177/1179552217752679 · 2018 · External reference
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
10.1177/1756283x11428502 · 2012 · External reference
Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers
10.3389/fmicb.2019.00336 · 2019 · External reference
Oral consumption of potential probiotic Saccharomyces boulardii strain Unique 28 in patients with acute diarrhoea: a clinical report
10.3920/bm2011.0055 · 2012 · External reference
Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study
10.1007/s10096-018-3267-x · 2018 · External reference
Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome
10.1007/s00384-019-03462-4 · 2020 · External reference
Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease
10.3920/bm2015.0018 · 2015 · External reference
In vitro study on the effect of Saccharomyces cerevisiae strains on growth and mycotoxin production by Aspergillus carbonarius and Fusarium graminearum
10.1016/j.ijfoodmicro.2012.11.016 · 2013 · External reference
Bioprospecting Kluyveromyces marxianus as a robust host for industrial biotechnology
10.3389/fbioe.2022.851768 · 2022 · External reference
A comparative evaluation of the kefir yeast Kluyveromyces marxianus A4 and sulfasalazine in ulcerative colitis: anti-inflammatory impact and gut microbiota modulation
10.1039/d4fo00427b · 2024 · External reference
In vitro investigation of Debaryomyces hansenii strains for potential probiotic properties
10.1007/s11274-016-2109-1 · 2016 · External reference
Sequence assembly of Yarrowia lipolytica strain W29/CLIB89 shows transposable element diversity
10.1371/journal.pone.0162363 · 2016 · External reference
Saccharomyces boulardii CNCM I-745
2017 · External reference
Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae
10.1128/aem.02201-06 · 2007 · External reference
Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii
10.1101/gr.243147.118 · 2019 · External reference
Saccharomyces boulardii CNCM I-745 supplementation during and after antibiotic treatment positively influences the bacterial gut microbiota
10.3389/fmed.2023.1087715 · 2023 · External reference
Clinical efficacy comparison of Saccharomyces boulardii and lactic acid as probiotics in acute pediatric diarrhea
10.29271/jcpsp.2018.03.214 · 2018 · External reference
Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation
10.1111/j.1365-2249.2009.03878.x · 2009 · External reference
Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis
10.1152/ajpgi.00217.2011 · 2011 · External reference
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease
10.1111/j.1572-0241.2006.00465.x · 2006 · External reference
Effectiveness of Saccharomyces boulardii CNCM I-745 in adult Indian patients with diarrhoea: a real-world, multicentre, retrospective, comparative study
10.1007/s40801-024-00424-3 · 2024 · External reference
A pilot trial of Saccharomyces boulardii in ulcerative colitis
10.1097/00042737-200306000-00017 · 2003 · External reference
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life
10.1097/mcg.0b013e318204593e · 2011 · External reference
Saccharomyces boulardii CNCM I-745 for prevention of antibiotic-associated diarrhea and Clostridioides difficile in China: systematic review and meta-analysis
2024 · External reference
Role of probiotics in the treatment and prevention of common gastrointestinal conditions in children
10.5223/pghn.2024.27.1.1 · 2024 · External reference
AGA Clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders
10.1053/j.gastro.2020.05.059 · 2020 · External reference
Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimdeurium mutant DT 104 to the surface of Saccharomyces boulardii
10.1046/j.1439-0507.1999.00449.x · 1999 · External reference
Modification of Salmonella typhimurium motility by the probiotic yeast strain Saccharomyces boulardii
10.1371/journal.pone.0033796 · 2012 · External reference
Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
10.1046/j.1365-2036.1999.00666.x · 1999 · External reference
Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance
10.1128/aem.00325-24 · 2024 · External reference
Gut microbial metabolites and its impact on human health
2023 · External reference
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
10.1128/iai.67.1.302-307.1999 · 1999 · External reference
Experimental effects of Saccharomyces boulardii on diarrheal pathogens
10.1016/s1286-4579(02)01592-7 · 2002 · External reference
Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl- secretion in T84 cells
10.1023/a:1026689628136 · 1999 · External reference
Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae
10.1128/aem.64.2.564-568.1998 · 1998 · External reference
Effectiveness of Saccharomyces boulardii in a rat model of colitis
10.3748/wjg.v18.i44.6452 · 2012 · External reference
Sacrosidase therapy for congenital sucrase-isomaltase deficiency
1999 · External reference
Comparative digestive physiology
10.1002/j.2040-4603.2013.tb00501.x · 2013 · External reference
Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats
10.1136/gut.45.1.89 · 1999 · External reference
Unique probiotic properties and bioactive metabolites of Saccharomyces boulardii
10.1007/s12602-022-09953-1 · 2023 · External reference
Saccharomyces boulardii CNCM I-745 supernatant improves markers of gut barrier function and inflammatory response in small intestinal organoids
10.3390/ph18081167 · 2025 · External reference
Regulation of intestinal barrier function by microbial metabolites
10.1016/j.jcmgh.2021.02.007 · 2021 · External reference
Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor
10.1371/journal.pone.0018427 · 2011 · External reference
Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii
10.1203/00006450-198602000-00020 · 1986 · External reference
Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition
10.3748/wjg.v11.i39.6165 · 2005 · External reference
Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial
10.1093/ofid/ofw011 · 2016 · External reference
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
10.3748/wjg.v16.i18.2202 · 2010 · External reference
Systematic review with meta-analysis: saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
10.1111/apt.13344 · 2015 · External reference
Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: a randomized controlled trial
10.1038/s41598-025-04986-2 · 2025 · External reference
Efficacy and safety of Saccharomyces boulardii CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis
10.3389/fcimb.2025.1587792 · 2025 · External reference
Application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness
10.4240/wjgs.v17.i2.102342 · 2025 · External reference
The effect of Saccharomyces boulardii primary prevention on risk of hospital-onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with C. difficile infection
10.1093/cid/ciaa808 · 2021 · External reference
Saccharomyces boulardii reduced intestinal inflammation in mice model of 2,4,6-trinitrobencene sulfonic acid induced colitis: based on microarray
10.4166/kjg.2010.55.1.33 · 2010 · External reference
Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression
10.1016/j.bbrc.2006.02.080 · 2006 · External reference
Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review
10.3390/nu15102275 · 2023 · External reference
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis
10.1007/s10620-008-0357-0 · 2008 · External reference
Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes
10.1053/j.gastro.2006.10.001 · 2006 · External reference
Comparative digestive physiology
10.1002/j.2040-4603.2013.tb00501.x · ExternalCitation · doi-reference
Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases
10.1007/s00284-020-02053-9 · ExternalCitation · doi-reference
Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome
10.1007/s00384-019-03462-4 · ExternalCitation · doi-reference
Lactic acid bacteria in Asian fermented foods and their beneficial roles in human health
10.1007/s10068-024-01634-9 · ExternalCitation · doi-reference
Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study
10.1007/s10096-018-3267-x · ExternalCitation · doi-reference
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis
10.1007/s10620-008-0357-0 · ExternalCitation · doi-reference
In vitro investigation of Debaryomyces hansenii strains for potential probiotic properties
10.1007/s11274-016-2109-1 · ExternalCitation · doi-reference
More information needed on probiotic supplement product labels
10.1007/s11606-019-05077-5 · ExternalCitation · doi-reference
Unique probiotic properties and bioactive metabolites of Saccharomyces boulardii
10.1007/s12602-022-09953-1 · ExternalCitation · doi-reference
Effectiveness of Saccharomyces boulardii CNCM I-745 in adult Indian patients with diarrhoea: a real-world, multicentre, retrospective, comparative study
10.1007/s40801-024-00424-3 · ExternalCitation · doi-reference
Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression
10.1016/j.bbrc.2006.02.080 · ExternalCitation · doi-reference
Probiotics-based foods and beverages as future foods and their overall safety and regulatory claims
10.1016/j.fufo.2021.100013 · ExternalCitation · doi-reference
In vitro study on the effect of Saccharomyces cerevisiae strains on growth and mycotoxin production by Aspergillus carbonarius and Fusarium graminearum
10.1016/j.ijfoodmicro.2012.11.016 · ExternalCitation · doi-reference
Regulation of intestinal barrier function by microbial metabolites
10.1016/j.jcmgh.2021.02.007 · ExternalCitation · doi-reference
Experimental effects of Saccharomyces boulardii on diarrheal pathogens
10.1016/s1286-4579(02)01592-7 · ExternalCitation · doi-reference
Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl- secretion in T84 cells
10.1023/a:1026689628136 · ExternalCitation · doi-reference
The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic
10.1038/nrgastro.2014.66 · ExternalCitation · doi-reference
Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: a randomized controlled trial
10.1038/s41598-025-04986-2 · ExternalCitation · doi-reference
A comparative evaluation of the kefir yeast Kluyveromyces marxianus A4 and sulfasalazine in ulcerative colitis: anti-inflammatory impact and gut microbiota modulation
10.1039/d4fo00427b · ExternalCitation · doi-reference
Introduction to the human gut microbiota
10.1042/bcj20160510 · ExternalCitation · doi-reference
Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
10.1046/j.1365-2036.1999.00666.x · ExternalCitation · doi-reference
Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimdeurium mutant DT 104 to the surface of Saccharomyces boulardii
10.1046/j.1439-0507.1999.00449.x · ExternalCitation · doi-reference
Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes
10.1053/j.gastro.2006.10.001 · ExternalCitation · doi-reference
AGA Clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders
10.1053/j.gastro.2020.05.059 · ExternalCitation · doi-reference
Bile acids as modulators of gut microbiota composition and function
10.1080/19490976.2023.2172671 · ExternalCitation · doi-reference
The effect of Saccharomyces boulardii primary prevention on risk of hospital-onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with C. difficile infection
10.1093/cid/ciaa808 · ExternalCitation · doi-reference
Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial
10.1093/ofid/ofw011 · ExternalCitation · doi-reference
A pilot trial of Saccharomyces boulardii in ulcerative colitis
10.1097/00042737-200306000-00017 · ExternalCitation · doi-reference
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life
10.1097/mcg.0b013e318204593e · ExternalCitation · doi-reference
Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii
10.1101/gr.243147.118 · ExternalCitation · doi-reference
Systematic review with meta-analysis: saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
10.1111/apt.13344 · ExternalCitation · doi-reference
Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation
10.1111/j.1365-2249.2009.03878.x · ExternalCitation · doi-reference
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease
10.1111/j.1572-0241.2006.00465.x · ExternalCitation · doi-reference
Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance
10.1128/aem.00325-24 · ExternalCitation · doi-reference
Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae
10.1128/aem.02201-06 · ExternalCitation · doi-reference
Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae
10.1128/aem.64.2.564-568.1998 · ExternalCitation · doi-reference
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
10.1128/iai.67.1.302-307.1999 · ExternalCitation · doi-reference
Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats
10.1136/gut.45.1.89 · ExternalCitation · doi-reference
Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis
10.1152/ajpgi.00217.2011 · ExternalCitation · doi-reference
Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review
10.1177/1179552217752679 · ExternalCitation · doi-reference
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
10.1177/1756283x11428502 · ExternalCitation · doi-reference
Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii
10.1203/00006450-198602000-00020 · ExternalCitation · doi-reference
Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor
10.1371/journal.pone.0018427 · ExternalCitation · doi-reference
Modification of Salmonella typhimurium motility by the probiotic yeast strain Saccharomyces boulardii
10.1371/journal.pone.0033796 · ExternalCitation · doi-reference
Sequence assembly of Yarrowia lipolytica strain W29/CLIB89 shows transposable element diversity
10.1371/journal.pone.0162363 · ExternalCitation · doi-reference
Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review
10.2147/ceg.s85574 · ExternalCitation · doi-reference
Clinical efficacy comparison of Saccharomyces boulardii and lactic acid as probiotics in acute pediatric diarrhea
10.29271/jcpsp.2018.03.214 · ExternalCitation · doi-reference
Bioprospecting Kluyveromyces marxianus as a robust host for industrial biotechnology
10.3389/fbioe.2022.851768 · ExternalCitation · doi-reference
Efficacy and safety of Saccharomyces boulardii CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis
10.3389/fcimb.2025.1587792 · ExternalCitation · doi-reference
Saccharomyces boulardii CNCM I-745 supplementation during and after antibiotic treatment positively influences the bacterial gut microbiota
10.3389/fmed.2023.1087715 · ExternalCitation · doi-reference
Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers
10.3389/fmicb.2019.00336 · ExternalCitation · doi-reference
Probiotics: mechanism of action, health benefits and their application in food industries
10.3389/fmicb.2023.1216674 · ExternalCitation · doi-reference
Effects of probiotics on gut microbiota: an overview
10.3390/ijms25116022 · ExternalCitation · doi-reference
Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives
10.3390/microorganisms12030430 · ExternalCitation · doi-reference
Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review
10.3390/nu15102275 · ExternalCitation · doi-reference
Prebiotics and probiotics for gastrointestinal disorders
10.3390/nu16060778 · ExternalCitation · doi-reference
Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review
10.3390/ph16111615 · ExternalCitation · doi-reference
Saccharomyces boulardii CNCM I-745 supernatant improves markers of gut barrier function and inflammatory response in small intestinal organoids
10.3390/ph18081167 · ExternalCitation · doi-reference
Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition
10.3748/wjg.v11.i39.6165 · ExternalCitation · doi-reference
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
10.3748/wjg.v16.i18.2202 · ExternalCitation · doi-reference
Effectiveness of Saccharomyces boulardii in a rat model of colitis
10.3748/wjg.v18.i44.6452 · ExternalCitation · doi-reference
Oral consumption of potential probiotic Saccharomyces boulardii strain Unique 28 in patients with acute diarrhoea: a clinical report
10.3920/bm2011.0055 · ExternalCitation · doi-reference
Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease
10.3920/bm2015.0018 · ExternalCitation · doi-reference
Saccharomyces boulardii reduced intestinal inflammation in mice model of 2,4,6-trinitrobencene sulfonic acid induced colitis: based on microarray
10.4166/kjg.2010.55.1.33 · ExternalCitation · doi-reference
Application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness
10.4240/wjgs.v17.i2.102342 · ExternalCitation · doi-reference
Role of probiotics in the treatment and prevention of common gastrointestinal conditions in children
10.5223/pghn.2024.27.1.1 · ExternalCitation · doi-reference
